Art

J-GLOBAL ID：201802281407886319   Reference number：18A2058003

Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase

未分化リンパ腫キナーゼにおけるI1171Tでの二次突然変異を伴う癌性髄膜炎に対するセリチニブ治療

Author (5)： Ashinuma Hironori (Division of Respiratory Medicine, Chiba Cancer Center, Japan) ,  Shingyoji Masato (Division of Respiratory Medicine, Chiba Cancer Center, Japan) ,  Hasegawa Yuzo (Division of Neurological Surgery, Chiba Cancer Center, Japan) ,  Yokoi Sana (Division of Translational Genomics, Chiba Cancer Center, Japan) ,  Yoshida Yasushi (Division of Respiratory Medicine, Chiba Cancer Center, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 57  Issue： 21  Page： 3153-3155(J-STAGE)  Publication year： 2018 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *Meningitis carcinomatosa ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2058003&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (5)： ALK ,  alectinib ,  ceritinib ,  I1171T ,  CSF

JST classification (3)： Clinical oncology in general  (GE03010Y) ,  Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Tumors(=neoplasms)of nervous system  (GN04000V)

Substance index (3)： Alectinib ,  Crizotinib ,  Ceritinib

Reference (10)：

• 1. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 7: 137-155, 2017.
• 2. Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK inhibitor (s) failure in advanced ALK positive non-small-cell lung cancer: analysis and literature review. Clin Lung Cancer 17: e77-e94, 2016.
• 3. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20: 5686-5696, 2014.
• 4. Ou SH, Klempner SJ, Greenbowe JR, et al. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol 9: 1821-1825, 2014.
• 5. Toyokawa G, Hirai F, Inamasu E, et al. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol 9: e86-e87, 2014.

Terms in the title (5)： 未分化リンパ腫キナーゼ ,  突然変異 ,  癌性髄膜炎 ,  セリチニブ ,  治療